BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35028141)

  • 1. Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous
    Rizzuto G; Leoncin M; Imbergamo S; Taurino D; Mico MC; Tosi M; Michelato A; Buklijas K; Spinelli O; Lussana F; Lessi F; Pizzi M; Bonaldi L; Binotto G; Rambaldi A; Gurrieri C
    Clin Case Rep; 2022 Jan; 10(1):e05212. PubMed ID: 35028141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
    Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
    Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
    Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
    Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
    Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
    Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
    Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
    Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
    Sun Y; Cai Y; Chen J; Cen J; Zhu M; Pan J; Wu D; Sun A; Chen S
    Front Oncol; 2021; 11():753842. PubMed ID: 34707996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea.
    Song I; Lee DH; Lee JH; Jang S; Huh JR; Seo EJ
    Ann Lab Med; 2016 Jan; 36(1):79-81. PubMed ID: 26522767
    [No Abstract]   [Full Text] [Related]  

  • 10. PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
    Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
    Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
    Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
    Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
    Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
    PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Wouters Y; Nevejan L; Louwagie A; Devos H; Dewaele B; Selleslag D; Michaux L
    Br J Haematol; 2021 Feb; 192(4):e112-e115. PubMed ID: 33502001
    [No Abstract]   [Full Text] [Related]  

  • 14. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
    Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
    Lierman E; Selleslag D; Smits S; Billiet J; Vandenberghe P
    Blood; 2012 Aug; 120(7):1529-31. PubMed ID: 22899477
    [No Abstract]   [Full Text] [Related]  

  • 17. Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene.
    Bellesso M; Santucci R; Dias DF; Centrone R; Elias RC
    Rev Bras Hematol Hemoter; 2013; 35(3):218-9. PubMed ID: 23904814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
    Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
    Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.
    Huang KP; Chase AJ; Cross NCP; Reiter A; Li TY; Wang TF; Chu SC; Lu XY; Li CC; Kao RH
    Int J Hematol; 2008 Sep; 88(2):197-201. PubMed ID: 18594780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report].
    Song Y; Zhang YR; Han Y; Wang Y; Li YQ; Chai Y; Zeng PY; Yue LL; Wu CY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):690. PubMed ID: 34547879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.